BME100 s2015:Group12 12pmL1: Difference between revisions
(6 intermediate revisions by 3 users not shown) | |||
Line 14: | Line 14: | ||
{| style="wikitable" width="700px" | {| style="wikitable" width="700px" | ||
|- valign="top" | |- valign="top" | ||
| [[Image: | | [[Image:BME103student.jpg|100px|thumb|Name: Corey Soto]] | ||
| [[Image:BME103student.jpg|100px|thumb|Name: Kyla Richardson]] | | [[Image:BME103student.jpg|100px|thumb|Name: Kyla Richardson]] | ||
| [[Image: | | [[Image:WaseemAljaid.jpg|100px|thumb|Name: Waseem Aljaid]] | ||
| [[Image:BME103student.jpg|100px|thumb|Name: Syeda Rizvi]] | | [[Image:BME103student.jpg|100px|thumb|Name: Syeda Rizvi]] | ||
| [[Image: | | [[Image:WillChmielewski.jpg|100px|thumb|Name: Will Chmielewski]] | ||
|} | |} | ||
Line 52: | Line 52: | ||
Assuming the team has access to the data for 10 mg of lipopolysacchride (LPS), Group A will be given an 8 mg sample of LPS. Using the ELISA method, samples of blood will be collected from Group A's subjects. Once data analysis is complete, Group A will be given a 6 mg dosage for the next trial. The experimental process for this study will repeat as the dosage of lipopolysacchiride is reduced by 2 mg each trial. Group B will be administered a placebo in place of lipopolysacchride, in order for data comparisons to be made between the groups. Their dosage will remain constant. This study was structured around current financial hardship the laboratory is undergoing; the study will have to be done by a trial-by-trial basis, in order to keep costs at a manageable level. | Assuming the team has access to the data for 10 mg of lipopolysacchride (LPS), Group A will be given an 8 mg sample of LPS. Using the ELISA method, samples of blood will be collected from Group A's subjects. Once data analysis is complete, Group A will be given a 6 mg dosage for the next trial. The experimental process for this study will repeat as the dosage of lipopolysacchiride is reduced by 2 mg each trial. Group B will be administered a placebo in place of lipopolysacchride, in order for data comparisons to be made between the groups. Their dosage will remain constant. This study was structured around current financial hardship the laboratory is undergoing; the study will have to be done by a trial-by-trial basis, in order to keep costs at a manageable level. | ||
With this reality in mind, if the results collected from each | With this reality in mind, if the results collected from each trial consistently show an increase in inflammotin levels, the team can narrow down on the range of LPS dosage values that may assist in accomplishing the study's objective. This could be the appropriate method for closing in on the minimal amount of lipopolysacchride required to increase the concentration of the inflammotin protein. | ||
Latest revision as of 19:18, 29 April 2015
BME 100 Spring 2015 | Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help | |||||
OUR TEAMLAB 1 WRITE-UPWARNING: All material presented here is highly suspectible to change by the write-up's authors. Final draft will be complete by Tuesday, 11:59 P.M. Independent and Dependent VariablesIndependent Variable: Lipopolysacchride (LPS) would be the variable the research team alters, because according to the ELISA data analysis regarding 10 mg LPS, the levels of inflammotin in the blood sample analyzed were affected by an amount of the drug. The team will be able to deduce how inflammotin levels interact with a certain dosage of LPS by manipulating this variable. Dependent Variable: Inflammotin is the protein responsible for inflammation and is the central part of the experiment the team will conduct. This variable will fluctuate based on the dosage of LPS the research team will administrator to the test groups. Experimental DesignGroups The data for 10 mg lipopolysacchride (LPS) will be used as a guide to set up the experiment, and will not have a trial dedicated to the dosage level.
With this reality in mind, if the results collected from each trial consistently show an increase in inflammotin levels, the team can narrow down on the range of LPS dosage values that may assist in accomplishing the study's objective. This could be the appropriate method for closing in on the minimal amount of lipopolysacchride required to increase the concentration of the inflammotin protein.
Age limit is between 60 to 70 years of age. The research team believes this is the prime demographic of elderly individuals whose personal health is adequate. These individuals are less likely to succumb to biological factors such as cell decay or organ failure, often from 71 years of age and older. Such issues may complicate the experiment.
Total: 20 subjects
Subject Selection
Sources of Error and Bias
|